Medilink Therapeutics develops next-generation antibody-drug conjugates (ADCs) that enhance the precision of cancer therapies by targeting tumor cells while minimizing damage to healthy tissue. Their technology addresses the limitations of traditional chemotherapy by improving treatment efficacy and expanding therapeutic windows for patients with unmet clinical needs.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer therapies like chemotherapy often lack precision, damaging healthy tissues alongside tumor cells, leading to significant side effects and limiting treatment efficacy. This lack of targeted drug delivery hinders the ability to maximize therapeutic benefits while minimizing harm to patients.
Solution
Medilink Therapeutics develops next-generation antibody-drug conjugates (ADCs) designed to enhance the precision of cancer therapies. Their technology platform focuses on creating ADCs that selectively target tumor cells, reducing off-target effects and improving the therapeutic window. By linking antibodies specific to cancer cell markers with potent cytotoxic drugs, Medilink aims to deliver targeted payloads directly to tumors, increasing efficacy and reducing systemic toxicity compared to traditional chemotherapy. This approach allows for higher drug concentrations at the tumor site while sparing healthy tissue, potentially leading to better patient outcomes and reduced side effects.
Target Audience
The primary target audience includes pharmaceutical companies, oncologists, and patients seeking more effective and less toxic cancer treatments.
Features
- Proprietary technology platforms for ADC development, enabling the creation of novel conjugates with improved targeting and payload delivery.
- Focus on developing ADCs with independent intellectual property rights and enhanced therapeutic windows.
- Pipeline of drug conjugates targeting various cancers with unmet clinical needs.
- Utilizes a senior ADC team covering the entire ADC development process.
- Collaborations with pharmaceutical companies to explore combinational potential of ADCs with other therapies.